Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data

No abstract is available for this paper.

• Publication year

  2015

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2015-01-01

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1111/bcp.12234PMID 24033787PMCID PMC4294076
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Physiologically Based Pharmacokinetic Modeling Science And Applications

  2016cited by this paper
• Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification

  2013cited by this paper
• Application of a Physiologically Based Pharmacokinetic Model to Assess Propofol Hepatic and Renal Glucuronidation in Isolation: Utility of In Vitro and In Vivo Data

  2013cited by this paper
• The Simcyp Population Based Simulator: Architecture, Implementation, and Quality Assurance

  2013cited by this paper
• A Physiologically Based Pharmacokinetic Model for Strontium Exposure in Rat

  2013cited by this paper
• Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential

  2013cited by this paper
• Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology

  2012cited by this paper
• A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution

  2012cited by this paper
• Applications of minimal physiologically-based pharmacokinetic models

  2012cited by this paper
• Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review

  2011cited by this paper
• Physiologically-based pharmacokinetics in drug development and regulatory science.

  2011cited by this paper
• Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model

  2011cited by this paper
• PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals.

  2010cited by this paper
• Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models

  2010cited by this paper
• A Bayesian population PBPK model for multiroute chloroform exposure

  2010cited by this paper
• Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin

  2010cited by this paper
• Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework.

  2009cited by this paper
• Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans

  2009cited by this paper
• A method for robust model order reduction in pharmacokinetics

  2009cited by this paper
• A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates.

  2009cited by this paper
• Identification of Intestinal Loss of a Drug through Physiologically Based Pharmacokinetic Simulation of Plasma Concentration-Time Profiles

  2008cited by this paper
• Methods for predicting in vivo pharmacokinetics using data from in vitro assays.

  2008cited by this paper
• Approaches for Applications of Physiologically Based Pharmacokinetic Models in Risk Assessment

  2008cited by this paper
• Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

  2007cited by this paper
• Data-based identifiability analysis of non-linear dynamical models

  2007cited by this paper
• Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

  2007cited by this paper
• Whole-body physiologically based pharmacokinetic models

  2007cited by this paper
• Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children

  2006cited by this paper
• Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA

  2006cited by this paper
• Diazepam Pharamacokinetics from Preclinical to Phase I Using a Bayesian Population Physiologically Based Pharmacokinetic Model with Informative Prior Distributions in Winbugs

  2006cited by this paper
• Reducing Whole Body Physiologically Based Pharmacokinetic Models Using Global Sensitivity Analysis: Diazepam Case Study

  2006cited by this paper
• Structural Identifiability of Physiologically Based Pharmacokinetic Models

  2006cited by this paper
• Optimal Design for Multivariate Response Pharmacokinetic Models

  2006cited by this paper
• Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.

  2006cited by this paper
• Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

  2005cited by this paper
• Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding

  2005cited by this paper
• Lumping in Pharmacokinetics

  2005cited by this paper
• Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.

  2005cited by this paper
• Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed.

  2005cited by this paper
• Population Pharmacokinetics II: Estimation Methods

  2004cited by this paper
• Whole Body Pharmacokinetic Models

  2003cited by this paper
• Basic anatomical and physiological data for use in radiological protection: reference values

  2002cited by this paper
• Use of Prior Information to Stabilize a Population Data Analysis

  2002cited by this paper
• Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects

  2001cited by this paper
• Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics.

  2001cited by this paper
• Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics.

  2000cited by this paper
• Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics.

  2000cited by this paper
• Statistical issues in toxicokinetic modeling: a bayesian perspective.

  2000cited by this paper
• Lumping of Whole-Body Physiologically Based Pharmacokinetic Models

  1998cited by this paper
• Simplification of Mathematical Models of Chemical Reaction Systems.

  1998cited by this paper
• Physiological Parameter Values for Physiologically Based Pharmacokinetic Models

  1997cited by this paper
• Structural identifiability of PBPK models: practical consequences for modeling strategies and study designs.

  1997cited by this paper
• Physiologically Based Pharmacokinetic Modeling of a Homologous Series of Barbiturates in the Rat: A Sensitivity Analysis

  1997cited by this paper
• Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions

  1996cited by this paper
• Bayesian analysis of population pharmacokinetic models.

  1996cited by this paper
• Uncertainty in fitted estimates of apparent in vivo metabolic constants for chloroform.

  1995cited by this paper
• Bayesian Analysis of Linear and Non‐Linear Population Models by Using the Gibbs Sampler

  1994cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993cited by this paper
• Optimization issues in physiological toxicokinetic modeling: a case study with benzene.

  1993cited by this paper
• Genetic Algorithms in Search Optimization and Machine Learning

  1988cited by this paper
• Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data

  1981cited by this paper
• Identifiable pharmacokinetic models: The role of extra inputs and measurements

  1980cited by this paper
• Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data

  1980cited by this paper
• Parameter and structural identifiability concepts and ambiguities: a critical review and analysis.

  1980cited by this paper
• Structural identifiability

  1977cited by this paper
• Lidocaine disposition kinetics in monkey and man; II. Effects of hemorrhage and sympathomimetic drug administration

  1974cited by this paper
• Lidocaine disposition kinetics in monkey and man; I. Prediction by a perfusion model

  1974cited by this paper
• Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration

  1937cited by this paper

• P-glycoprotein-Mediated Impairment of Doxorubicin Clearance in Inflammatory Bowel Disorders: Mechanistic Insights from Rat Studies and Whole-Body PBPK Modeling

  2026cites this paper
• Integrating Population Approaches With Physiologically Based Pharmacokinetic Models: A Novel Framework for Parameter Estimation

  2026cites this paper
• Exploiting Pharmacokinetic/Pharmacodynamic Methods for Optimizing and Accelerating Drug Development of Innovative Anti‐Infectives

  2026cites this paper
• Review on Predictive Models and Integration Strategies for Holistic Impact Assessment of Chemicals and Materials

  2026cites this paper
• A minimal PBPK model for predicting the metabolism of tenofovir prodrugs in the liver of human with fibrosis

  2026cites this paper
• Exposure and tissue distribution analyses of brominated flame retardants in Neophocaena phocaenoides through physiologically based toxicokinetic (PBTK) modeling.

  2025cites this paper
• Characterization of small molecule drug clearance mechanisms using in vitro and in vivo approaches in drug discovery and development

  2025cites this paper
• Cytochrome P450 reaction phenotyping: State of the art.

  2025cites this paper
• Chemical risk assessment in food animals via physiologically based pharmacokinetic modeling - Part I: Veterinary drugs on human food safety assessment.

  2025cites this paper
• A preliminary exploration of liver microsomes and PBPK to uncover the impact of CYP3A4/5 and CYP2C19 on tacrolimus and voriconazole drug-drug interactions

  2025cites this paper
• Virtual Humans in Drug Development: Integrating Digital Models with Pharmacological Science

  2025cites this paper
• Generating Realistic Albumin Concentrations in Virtual Subjects Across A Spectrum of Renal Function to Account for Variability in Protein Binding Within PBPK Models

  2025cites this paper
• Beyond Michaelis-Menten: A Modified Enzyme Kinetics Equation Improves Drug Metabolism Prediction in Bottom-Up PBPK Modeling.

  2025cites this paper
• Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio

  2025cites this paper
• Application of Physiologically-Based Pharmacokinetic (PBPK) Model in Drug Development and in Dietary Phytochemicals

  2025cites this paper
• Beyond traditional toxicology: The transformative power of PBTK modeling

  2025cites this paper
• Solubility-Limited Absorption Identified by a Simplified PBPK Model for the Prediction of Positive Food Effect for BCS II/IV Drugs

  2025cites this paper
• Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study

  2025cites this paper
• A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions

  2024cites this paper
• Computational approaches to predict the toxicity of bioactive natural products: a mini review of methodologies

  2024cites this paper
• Facing the facts of altered plasma protein binding: Do current models correctly predict changes in fraction unbound in special populations?

  2024cites this paper
• Quantitative pulmonary pharmacokinetics of tetrandrine for SARS-CoV-2 repurposing: a physiologically based pharmacokinetic modeling approach

  2024cites this paper
• Parameter grouping and co-estimation in physiologically based kinetic models using genetic algorithms

  2024cites this paper
• Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects

  2024cites this paper
• A physiologically‐based pharmacokinetic/pharmacodynamic modeling approach for drug–drug‐gene interaction evaluation of S‐warfarin with fluconazole

  2024cites this paper
• Mathematical Models of Ocular Drug Delivery

  2024influential citation
• Beyond the basics: A deep dive into parameter estimation for advanced PBPK and QSP models.

  2024cites this paper
• Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape

  2024cites this paper
• Advancing Ecotoxicological Studies: Utilizing New Approach Methodologies to Enable Cross-Species Extrapolation and Reduce Avian Testing.

  2024cites this paper
• A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam

  2024cites this paper
• Utility of Life Stage-Specific Chemical Risk Assessments Based on New Approach Methodologies (NAMs).

  2024cites this paper
• Analyzing Parametric Influences Driving Age-Associated Changes in Absorption using a PBPK-GSA Approach.

  2024cites this paper
• Utility of PBPK Modeling in Predicting and Characterizing Clinical Drug Interactions.

  2024cites this paper
• The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling

  2024influential citation
• A Meta-Analysis Methodology in Stan to Estimate Population Pharmacokinetic Parameters from Multiple Aggregate Concentration–Time Datasets: Application to Gevokizumab mPBPK Model

  2024cites this paper
• Physiologically based kinetic (PBK) modeling of propiconazole using a machine learning-enhanced read-across approach for interspecies extrapolation.

  2024cites this paper
• Integrated Use of In Vitro and In Vivo Information for Comprehensive Prediction of Drug Interactions Due to Inhibition of Multiple CYP Isoenzymes

  2023cites this paper
• A Physiologically Based Pharmacokinetic Model to Predict Determinants of Variability in Epirubicin Exposure and Tissue Distribution

  2023cites this paper
• Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations

  2023cites this paper
• All Roads Lead to Rome: Enhancing the Probability of Target Attainment with Different Pharmacokinetic/Pharmacodynamic Modelling Approaches

  2023cites this paper
• A Physiologically-Based Pharmacokinetic Model for Cannabidiol in Healthy Adults, Hepatically-Impaired Adults, and Children

  2023cites this paper
• Practical Understanding of Cancer Model Identifiability in Clinical Applications

  2023cites this paper
• A “middle‐out approach” for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models

  2023cites this paper
• Using Prior Knowledge on Systems Through PBPK to Gain Further Insight into Routine Clinical Data on Trough Concentrations: The Case of Tacrolimus in Chronic Kidney Disease

  2023cites this paper
• Nanoparticle Biodistribution Coefficients: A Quantitative Approach for Understanding the Tissue Distribution of Nanoparticles.

  2023cites this paper
• The Global Bioequivalence Harmonisation Initiative (GBHI): Report of the fifth international EUFEPS/AAPS conference.

  2023cites this paper
• Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin

  2023cites this paper
• PBPK modeling as an alternative method of extrapolation interspecies that reduce the use of animals: a systematic review...

  2023cites this paper
• Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach

  2023cites this paper
• Investigation of simplified physiologically‐based pharmacokinetic models in rat and human

  2023cites this paper
• A novel physiologically based pharmacokinetic model of rectal absorption, evaluated and verified using clinical data on 10 rectally administered drugs.

  2023cites this paper
• Pharmacometrics: A New Era of Pharmacotherapy and Drug Development in Low- and Middle-Income Countries

  2023cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modelling of Oral Drug Absorption in Older Adults - an AGePOP review.

  2023cites this paper
• Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling

  2022cites this paper
• Integration of Engineered Delivery with the Pharmacokinetics of Medical Candidates via Physiology-Based Pharmacokinetics.

  2022cites this paper
• Atypical kinetics of cytochrome P450 enzymes in pharmacology and toxicology.

  2022cites this paper
• Insights into the mapping of green synthesis conditions for ZnO nanoparticles and their toxicokinetics.

  2022cites this paper
• Approaches of formulation bridging in support of orally administered drug product development.

  2022cites this paper
• Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats.

  2022cites this paper
• Physiologically based pharmacokinetic (PBPK) modeling of lornoxicam: Exploration of doses for CYP2C9 genotypes and patients with cirrhosis.

  2022cites this paper
• A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections

  2022influential citation
• Prediction of Drug–Drug–Gene Interaction Scenarios of (E)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling

  2022cites this paper
• Development of a Translational Model to Assess the Impact of Opioid Overdose and Naloxone Dosing on Respiratory Depression and Cardiac Arrest

  2022cites this paper
• Enhanced prediction of internal concentrations of phenolic endocrine disrupting chemicals and their metabolites in fish by a physiologically based toxicokinetic incorporating metabolism (PBTK-MT) model.

  2022cites this paper
• Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective

  2022cites this paper
• Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?

  2022cites this paper
• Predictive Performance of Next Generation Human Physiologically Based Kinetic (PBK) Models Based on In Vitro and In Silico Input Data

  2022cites this paper
• The Use of Physiologically Based Pharmacokinetic Analyses—in Biopharmaceutics Applications -Regulatory and Industry Perspectives

  2022cites this paper
• A PBPK Model of Ternary Cyclodextrin Complex of ST-246 Was Built to Achieve a Reasonable IV Infusion Regimen for the Treatment of Human Severe Smallpox

  2022cites this paper
• Streamlining physiologically‐based pharmacokinetic model design for intravenous delivery of nanoparticle drugs

  2022cites this paper
• In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition

  2022cites this paper
• A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes.

  2022cites this paper
• Predictive performance of next generation human physiologically based kinetic (PBK) model predictions based on in vitro and in silico input data_suppl1

  2022cites this paper
• Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human

  2022cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modeling of RNAi Therapeutics: Opportunities and Challenges.

  2021cites this paper
• RESOLVING THE CHALLENGES TO ESTABLISHING CONFIDENCE IN PBPK MODELS

  2021cites this paper
• Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network.

  2021cites this paper
• Moving From Point‐Based Analysis to Systems‐Based Modeling: Integration of Knowledge to Address Antimicrobial Resistance Against MDR Bacteria

  2021cites this paper
• Physiologically Based Pharmacokinetic Modeling: Definition and History

  2021cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modeling: Model Development and Evaluation

  2021cites this paper
• Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors

  2021cites this paper
• Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation

  2021cites this paper
• Understanding Mechanisms of Food Effect and Developing Reliable PBPK Models Using a Middle-out Approach

  2021cites this paper
• The Development of a PBPK Model for Atomoxetine Using Levels in Plasma, Saliva and Brain Extracellular Fluid in Patients with Normal and Deteriorated Kidney Function.

  2021cites this paper
• Hepatic transporter‐mediated pharmacokinetic drug–drug interactions: Recent studies and regulatory recommendations

  2021cites this paper
• Report of the Synthesis and Integration of Epidemiological and Toxicological Evidence Subgroup (SETE) of the Committee on Toxicity and the Committee on Carcinogenicity

  2021cites this paper
• Modeling Pharmacokinetic Natural Product–Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach

  2021cites this paper
• Physiologically‐Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome

  2021cites this paper
• Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats

  2021cites this paper
• Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans

  2021cites this paper
• Modelling Tools to Characterize Acetaminophen Pharmacokinetics in the Pregnant Population

  2021cites this paper
• Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?

  2021cites this paper
• Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making

  2021cites this paper
• Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3

  2021cites this paper
• Lost in modelling and simulation?

  2021cites this paper
• Twice neglected? Neglected diseases in neglected populations

  2021cites this paper
• Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective.

  2021cites this paper
• Predictive Performance of Next Generation Physiologically Based Kinetic (PBK) Model Predictions in Rats Based on In Vitro and In Silico Input Data

  2021cites this paper
• Experimental Data and PBPK Modeling Quantify Antibody Interference in PEGylated Drug Carrier Delivery

  2021cites this paper
• Report of the Synthesis and Integration of Epidemiological and Toxicological Edidence Subgroup

  2021cites this paper